Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells

Chaim M. Roifman, Gordon Mills, Mary Chu, Erwin W. Gelfand

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Due to its purity and potential availability in large amounts, human recombinant interleukin 2 (IL-2) expressed in Escherichia coli is an important source of IL-2 for experimentation and possible therapy. To date, very few comparisons between the activity of recombinant IL-2 and conventional cell-derived preparations of IL-2 have been made. This is particularly important since the use of recombinant IL-2 may have some specific limitations. For example, recombinant IL-2 is not post-translationally modified as are cell-derived preparations. Lack of modifications such as glycosylation of threonine 3 may alter efficacy or stability. Comparative studies are necessary to demonstrate the efficacy, species specificity, and stability of recombinant IL-2. By comparing IL-2 activity of recombinant IL-2 to that of cell-derived IL-2, we have demonstrated that each of the preparations are equally active in several murine and human IL-2 proliferation assays and that IL-2 is the active moiety in these assays. In contrast to previous reports, we also show that recombinant IL-2 is sufficient to establish and maintain long-term cell lines. Additionally, by using "synthetic" recombinant IL-2 of defined protein sequence, we have demonstrated that this amino acid-defined structure is indeed responsible for the functions attributed to IL-2.

Original languageEnglish (US)
Pages (from-to)146-156
Number of pages11
JournalCellular Immunology
Volume95
Issue number1
DOIs
StatePublished - Oct 1 1985
Externally publishedYes

Fingerprint

Interleukin-2
Cultured Cells
Species Specificity
Threonine
Glycosylation
Escherichia coli

ASJC Scopus subject areas

  • Immunology

Cite this

Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. / Roifman, Chaim M.; Mills, Gordon; Chu, Mary; Gelfand, Erwin W.

In: Cellular Immunology, Vol. 95, No. 1, 01.10.1985, p. 146-156.

Research output: Contribution to journalArticle

@article{7bacde5f1777499fa78f08cf464b0350,
title = "Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells",
abstract = "Due to its purity and potential availability in large amounts, human recombinant interleukin 2 (IL-2) expressed in Escherichia coli is an important source of IL-2 for experimentation and possible therapy. To date, very few comparisons between the activity of recombinant IL-2 and conventional cell-derived preparations of IL-2 have been made. This is particularly important since the use of recombinant IL-2 may have some specific limitations. For example, recombinant IL-2 is not post-translationally modified as are cell-derived preparations. Lack of modifications such as glycosylation of threonine 3 may alter efficacy or stability. Comparative studies are necessary to demonstrate the efficacy, species specificity, and stability of recombinant IL-2. By comparing IL-2 activity of recombinant IL-2 to that of cell-derived IL-2, we have demonstrated that each of the preparations are equally active in several murine and human IL-2 proliferation assays and that IL-2 is the active moiety in these assays. In contrast to previous reports, we also show that recombinant IL-2 is sufficient to establish and maintain long-term cell lines. Additionally, by using {"}synthetic{"} recombinant IL-2 of defined protein sequence, we have demonstrated that this amino acid-defined structure is indeed responsible for the functions attributed to IL-2.",
author = "Roifman, {Chaim M.} and Gordon Mills and Mary Chu and Gelfand, {Erwin W.}",
year = "1985",
month = "10",
day = "1",
doi = "10.1016/0008-8749(85)90303-X",
language = "English (US)",
volume = "95",
pages = "146--156",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells

AU - Roifman, Chaim M.

AU - Mills, Gordon

AU - Chu, Mary

AU - Gelfand, Erwin W.

PY - 1985/10/1

Y1 - 1985/10/1

N2 - Due to its purity and potential availability in large amounts, human recombinant interleukin 2 (IL-2) expressed in Escherichia coli is an important source of IL-2 for experimentation and possible therapy. To date, very few comparisons between the activity of recombinant IL-2 and conventional cell-derived preparations of IL-2 have been made. This is particularly important since the use of recombinant IL-2 may have some specific limitations. For example, recombinant IL-2 is not post-translationally modified as are cell-derived preparations. Lack of modifications such as glycosylation of threonine 3 may alter efficacy or stability. Comparative studies are necessary to demonstrate the efficacy, species specificity, and stability of recombinant IL-2. By comparing IL-2 activity of recombinant IL-2 to that of cell-derived IL-2, we have demonstrated that each of the preparations are equally active in several murine and human IL-2 proliferation assays and that IL-2 is the active moiety in these assays. In contrast to previous reports, we also show that recombinant IL-2 is sufficient to establish and maintain long-term cell lines. Additionally, by using "synthetic" recombinant IL-2 of defined protein sequence, we have demonstrated that this amino acid-defined structure is indeed responsible for the functions attributed to IL-2.

AB - Due to its purity and potential availability in large amounts, human recombinant interleukin 2 (IL-2) expressed in Escherichia coli is an important source of IL-2 for experimentation and possible therapy. To date, very few comparisons between the activity of recombinant IL-2 and conventional cell-derived preparations of IL-2 have been made. This is particularly important since the use of recombinant IL-2 may have some specific limitations. For example, recombinant IL-2 is not post-translationally modified as are cell-derived preparations. Lack of modifications such as glycosylation of threonine 3 may alter efficacy or stability. Comparative studies are necessary to demonstrate the efficacy, species specificity, and stability of recombinant IL-2. By comparing IL-2 activity of recombinant IL-2 to that of cell-derived IL-2, we have demonstrated that each of the preparations are equally active in several murine and human IL-2 proliferation assays and that IL-2 is the active moiety in these assays. In contrast to previous reports, we also show that recombinant IL-2 is sufficient to establish and maintain long-term cell lines. Additionally, by using "synthetic" recombinant IL-2 of defined protein sequence, we have demonstrated that this amino acid-defined structure is indeed responsible for the functions attributed to IL-2.

UR - http://www.scopus.com/inward/record.url?scp=0022007279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022007279&partnerID=8YFLogxK

U2 - 10.1016/0008-8749(85)90303-X

DO - 10.1016/0008-8749(85)90303-X

M3 - Article

VL - 95

SP - 146

EP - 156

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 1

ER -